Obstetrics & Gynecology Track the topics, authors and articles important to you
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Obstetrics & Gynecology 1992;79:223-228
© 1992 by The American College of Obstetricians and Gynecologists
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by CARLAN, S. J.
Right arrow Articles by MASTROGIANNIS, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by CARLAN, S. J.
Right arrow Articles by MASTROGIANNIS, D.

Randomized Comparative Trial of Indomethacin and Sulindac for the Treatment of Refractory Preterm Labor

STEPHEN J. CARLAN, MD, WILLIAM F. O'BRIEN, MD, TIMOTHY D. O'LEARY, MD and DIMITRIOS MASTROGIANNIS, MD, PhD

From the Department of Obstetrics and Gynecology, University of South Florida College of Medicine, Tampa, Florida

Abstract

This study was designed to investigate the efficacy and safety of sulindac in the treatment of preterm labor. Thirty-six women in preterm labor who had failed initial attempts at tocolysis with magnesium sulfate were randomized to receive either oral indomethacin or oral sulindac for 48 hours. The mean gestational ages at admission were 29 and 30 weeks for the sulindac and indomethacin groups, respectively. There was a significantly greater hourly fetal urine output, deepest amniotic fluid pocket, and amniotic fluid index in the sulindac group. A trend toward higher fetal ductus arteriosus flow velocities noted in the indomethacin group was not seen in the sulindac group. The drugs had similar success in delaying delivery for 48 hours or 7 days. The mean birth weights were 2000 and 2323 g for the sulindac and indomethacin groups, respectively. Sulindac appears to be as effective as indomethacin for refractory preterm labor but with fewer fetal side effects.




This article has been cited by other articles:


Home page
 Obstet GynecolHome page
S. M. Loe, L. Sanchez-Ramos, and A. M. Kaunitz
Assessing the Neonatal Safety of Indomethacin Tocolysis: A Systematic Review With Meta-Analysis
Obstet. Gynecol., July 1, 2005; 106(1): 173 - 179.
[Abstract] [Full Text] [PDF]

Home page
 Obstet GynecolHome page
R. G. Humphrey, M. C. Bartfield, S. J. Carlan, W. F. O'Brien, T. D. O'Leary, and T. Triana
Sulindac to Prevent Recurrent Preterm Labor: A Randomized Controlled Trial
Obstet. Gynecol., October 1, 2001; 98(4): 555 - 562.
[Abstract] [Full Text] [PDF]

Home page
 Arch. Dis. Child. Fetal Neonatal Ed.Home page
S. Vause and T. Johnston
Management of preterm labour
Arch. Dis. Child. Fetal Neonatal Ed., September 1, 2000; 83(2): 79F - 85.
[Full Text]

Home page
 Pharmacol. Rev.Home page
G. C. S. Smith
The Pharmacology of the Ductus Arteriosus
Pharmacol. Rev., March 1, 1998; 50(1): 35 - 58.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1992 by the American College of Obstetricians and Gynecologists.